Alzheimer's Disease Clinical Trial
Official title:
Biochemical and Genetic Studies in Familial Alzheimer's Disease
Alzheimer's disease is a condition marked by the deterioration of mental function. The
disease usually begins in late middle life and results in death in 5 to 10 years. Patients
with Alzheimer's disease typically suffer from memory loss, confusion, and disorientation.
The condition has become a major medical and social problem in the United States because of
the increasing number of people living beyond the age of 65. The actual cause of Alzheimer's
disease is unknown.
Researchers believe that Alzheimer's disease, or at least a portion of cases, may be an
inherited condition. As a result, many new techniques have been developed to study the
genetic causes of Alzheimer's disease and other neurological disorders. Many of these
genetic techniques require blood samples and a family pedigree. A pedigree is a chart,
similar to a family tree, that shows a patient's family history.
The purpose of this study is to collect family and psychosocial information, blood, and
biopsy samples from patients with neurological diseases, their families, and normal
volunteers. This information gathered will be used to learn more about diseases that affect
the brain.
This is a screening and follow-up Protocol. Recent technological advances have facilitated the development of new approaches for investigating the underlying genetic basis of neurological disorders, but genetic questions remain open and on going. Application of many genetic techniques require a family pedigree and blood sample. Peripheral blood lymphoblasts which are banked also serve as a renewable source for harvesting DNA which can be used for developing genetic markers in the future. This study will allow collection of family and psychosocial information and blood specimens from patients with neurological diseases, their families, and normal control subjects. ;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Withdrawn |
NCT03316898 -
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
|
Phase 1 | |
Withdrawn |
NCT02860065 -
CPC-201 Alzheimer's Disease Type Dementia: PET Study
|
Phase 2 | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Recruiting |
NCT05607615 -
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
|
Phase 2 | |
Terminated |
NCT03307993 -
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
|
Phase 1 | |
Recruiting |
NCT02912936 -
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
|
N/A | |
Active, not recruiting |
NCT02899091 -
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02868905 -
Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women
|
N/A | |
Completed |
NCT02907567 -
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02580305 -
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
|
Phase 2 | |
Terminated |
NCT02521558 -
Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease
|
N/A | |
Completed |
NCT02516046 -
18F-AV-1451 Autopsy Study
|
Phase 3 | |
Recruiting |
NCT02247180 -
Cognitive Rehabilitation in Alzheimer`s Disease
|
N/A | |
Completed |
NCT02260167 -
Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol
|
N/A | |
Completed |
NCT02256306 -
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
|
N/A | |
Terminated |
NCT02220738 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
|
Phase 1 | |
Completed |
NCT02317523 -
Alzheimer's Caregiver Coping: Mental and Physical Health
|
N/A | |
Completed |
NCT01920672 -
Disrupted Sleep, Neuroendocrine Status and the Behavioral Symptoms of AD
|
N/A |